- Home
- JTAI vs APM Comparison
JTAI vs APM Comparison
Compare JTAI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- APM
- Stock Information
- Founded
- JTAI 2018
- APM 2010
- Country
- JTAI United States
- APM United Kingdom
- Employees
- JTAI N/A
- APM N/A
- Industry
- JTAI Blank Checks
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- APM Health Care
- Exchange
- JTAI Nasdaq
- APM Nasdaq
- Market Cap
- JTAI 8.3M
- APM 6.9M
- IPO Year
- JTAI N/A
- APM 2018
- Fundamental
- Price
- JTAI $3.42
- APM $2.64
- Analyst Decision
- JTAI Strong Buy
- APM
- Analyst Count
- JTAI 1
- APM 0
- Target Price
- JTAI $11.00
- APM N/A
- AVG Volume (30 Days)
- JTAI 67.8K
- APM 20.0M
- Earning Date
- JTAI 08-15-2025
- APM 04-30-2025
- Dividend Yield
- JTAI N/A
- APM N/A
- EPS Growth
- JTAI N/A
- APM N/A
- EPS
- JTAI N/A
- APM N/A
- Revenue
- JTAI $12,790,684.00
- APM N/A
- Revenue This Year
- JTAI $13.37
- APM N/A
- Revenue Next Year
- JTAI $201.13
- APM N/A
- P/E Ratio
- JTAI N/A
- APM N/A
- Revenue Growth
- JTAI N/A
- APM N/A
- 52 Week Low
- JTAI $2.30
- APM $0.46
- 52 Week High
- JTAI $57.17
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- JTAI 52.51
- APM 59.96
- Support Level
- JTAI $3.01
- APM $1.26
- Resistance Level
- JTAI $3.54
- APM $4.47
- Average True Range (ATR)
- JTAI 0.17
- APM 0.26
- MACD
- JTAI 0.02
- APM 0.17
- Stochastic Oscillator
- JTAI 77.36
- APM 43.87
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.